The law under consideration “delinks” PBM compensation from manufacturer rebates in Medicare and requires flat administrative fees, certified at fair market value. It also mandates that rebates be passed through to health plan sponsors in the employer-sponsored market. This sounds appealing, but incentives matter. When compensation no longer depends on securing better terms, bargaining effort becomes a cost center rather than a profit center. PBMs will still compete for contracts, but competition on administrative fees isn’t the same as competition on aggressive price concessions and won’t lower drug prices.
Watch: How could Trump respond to Iran crackdown?，这一点在爱思助手下载最新版本中也有详细论述
Вашингтон Кэпиталз。业内人士推荐同城约会作为进阶阅读
有案必立、有诉必理，各级法院登记立案数量持续上升，法院“案多人少”矛盾更加突出。。关于这个话题，体育直播提供了深入分析
Захарова поинтересовалась возможностью посмотреть «Терминатора» в Молдавии14:59